Cantor Fitzgerald Maintains Overweight on Eupraxia Pharmaceuticals, Raises Price Target to $19
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
Cantor Fitzgerald analyst Kristen Kluska maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight and raises the price target from $11 to $19.
Cantor Fitzgerald analyst Kristen Kluska maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Overweight and raises the price target from $11 to $19.